<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328404</url>
  </required_header>
  <id_info>
    <org_study_id>VitD31.0</org_study_id>
    <nct_id>NCT02328404</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>The Effect of Vitamin D Supplementation on Chromium Serum Levels and Insulin Resistance Among Overweight Jordanian Women With Polycystic Ovary Syndrome in Irbid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hayat Pharmaceutical Co. PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hayat Pharmaceutical Co. PLC</source>
  <oversight_info>
    <authority>Jordan: Jordanian Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of 50,000 IU vitamin D3 supplementation
      on Polycystic Ovary Syndrome prognosis.

      A randomized, double-blind, Parallel design comparing vitamin D with Placebo will be
      conducted on 60 overweight females diagnosed with PCOS according to Rotterdam criteria and
      have serum 25(OH)D level &lt; 20 ng/ml. The results are expected to assess the improvement of
      Polycystic Ovary Syndrome prognosis and the effect of Vitamin D Supplementation on Chromium
      Serum Levels and Insulin Resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      controlled randomised double blind study to examine the Effect of Vitamin D Supplementation
      on Chromium Serum Levels and Insulin Resistance among Overweight Jordanian Women with
      Polycystic Ovary Syndrome in Irbid. comparing vitamin D with Placebo will be conducted on 60
      overweight females diagnosed with PCOS according to Rotterdam criteria and have serum
      25(OH)D level &lt; 20 ng/ml. Evaluation of the effectiveness of the dose regimen considered in
      this study as the product SmPC which will be measured through the assessment of serum 25
      (OH)D along the trial period. the expected duration of participants participation will be
      around 104 days divided on 6 visits. the first visit will be 7 days before the beginning of
      the study, the second will be at day 0 of the trial to measure the baseline, third vist at
      day 30, then at day 60, then at day 90 and the final visit will be after 104 days of study.
      The results are expected to assess the improvement of PCOS prognosis and the effect of
      Vitamin D Supplementation on Chromium Serum Levels and Insulin Resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progesterone Level After 3 Months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>improvement of Polycystic ovary syndrome prognosis which will be measured through improving progesterone level( Regular menstruation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of Polycystic Ovary Syndrome Prognosis Through Decreasing Hirsutism Score &lt; 8 .</measure>
    <time_frame>3months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>improvement of Polycystic ovary syndrome prognosis which will be measured through decreasing hirsutism score &lt; 8 . A total of 9 body sites were assessed, the score ranging from 0 (no excessive terminal hair growth) to 36 (extensive terminal hair growth). A score of 8 or higher was considered as androgen excess (Ferriman and Gallwey, 1961).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PTH.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of 50,000 IU Vitamin D3 Supplementation on Serum Hydroxy Vitamin D Levels.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of the effectiveness of the dose regimen considered in this study as the product SmPC which will be measured through the assessment of serum 25 (OH)D along the trial period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reduction of body mass index to be &lt; 25-30 kg/m^2 after 3 months supplementaion of vitamin D3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance and Improving Insulin Sensitivity After Vitamin D3 Supplementation for 3 Months.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reduction of insulin resistance and improving insulin sensitivity measured by HOMMA method through reducing fasting insulin to be &lt; 24 uU/ml after vitamin D3 supplementation for 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Chromium Level After Supplementation With Vitamin D3.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>serum chromium level to be &gt; 0.05 and &lt; 0.5 ppm which will be assessed by measuring serum chromium level after supplementation of vitamin D3 for 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PO4.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of Ca.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>vitamin D3 (Biodal 50.000IU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo coated tablet by oral route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50.000IU Vitamin D3</intervention_name>
    <description>50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
    <arm_group_label>vitamin D3 (Biodal 50.000IU)</arm_group_label>
    <other_name>Biodal 50.000IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo coated tablet by oral route</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Ethnic group (Caucasian).

          -  Healthy females aged between 18 and 49 years old.

          -  Overweight (BMI 25-30 kg/m2).

          -  Physical examination being assessed and accepted by the attending physician.

          -  systolic blood pressure within the normal range (90-140 mmHg).

          -  Diastolic blood pressure within the normal range (60-90 mmHg).

          -  Heart rate within the normal range (60-100 beat/min).

          -  Oral body temperature within the normal range (35.9 - 37.6 Cáµ’).

          -  Diagnosed with Polycystic ovary syndrome according to Rotterdam criteria (Rotterdam
             SHRE-ASRM Sponsored Polycystic ovary syndrome consensus workshop group, 2004).

          -  Women have serum 25(OH)D level &lt; 20 ng/ml.

          -  Women have inadequate dietary intake of vitamin D (&lt;600 IU/day or &lt;15Î¼g/day)

          -  Normal complete blood count , Liver Function enzymes test (AST, ALT) and Kidney
             unction tests (Urea, Creatinine).

          -  Able and willing to comply with all study requirements.

        Exclusion Criteria:

          -  Female participants who is pregnant, lactating or planning pregnancy during the
             course of the study.

          -  Ethnic group non Caucasian.

          -  Females aged &lt;18 or &gt;49 years old.

          -  Underweight, normal body weight and obese Females.

          -  Females diagnosed with diabetes, hypothyroidism, hyperthyroidism, liver disease,
             renal dysfunction, cardiovascular diseases, androgen-secreting tumor, Cushing
             syndrome, congenital adrenal hyperplasia, hyperprolactinemia, and/or virilism.

          -  Known history or presence of food allergies or intolerance (e.g dairy products or
             gluten containing food), or any known condition that could interfere with the
             absorption, distribution, metabolism or execration of drugs.

          -  History of drug or alcohol abuse, smoking of 10 cigarettes or more (or equivalent)
             per day.

          -  Participants who took medications known to affect metabolic parameters, such as
             metformin and corticosteroid drugs, vitamin D and calcium.

          -  Women who have adequate dietary intake of vitamin D (600 IU/day or 15Î¼g/day).

          -  Participation in another clinical or bioequivalence study within 90 days prior to the
             start of this study period.

          -  Participants with abnormal ECG.

          -  Participants with any abnormal laboratory results except [ 25(OH)D, Cr, Ca,
             phosphate, C reactive protein , triglyceride ,HDL-C, LDL-C, total cholesterol/high
             density lipoprotein-cholesterol ratio , fasting insulin , fasting blood glucose, oral
             glucose tolerance test , impaired glucose tolerance , Pr, total testosterone , sex
             hormone binding globulin ,parathyroid hormone and free androgen index .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>April 14, 2015</lastchanged_date>
  <firstreceived_date>December 14, 2014</firstreceived_date>
  <firstreceived_results_date>January 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3 (Biodal 50.000IU)</title>
          <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3 (Biodal 50.000IU)</title>
          <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28.26" lower_limit="18" upper_limit="49"/>
                <measurement group_id="B2" value="28.26" lower_limit="18" upper_limit="49"/>
                <measurement group_id="B3" value="28.26" lower_limit="18" upper_limit="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Jordan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progesterone Level After 3 Months</title>
        <description>improvement of Polycystic ovary syndrome prognosis which will be measured through improving progesterone level( Regular menstruation).</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progesterone Level After 3 Months</title>
            <description>improvement of Polycystic ovary syndrome prognosis which will be measured through improving progesterone level( Regular menstruation).</description>
            <units>nmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.8" spread="1.86"/>
                  <measurement group_id="O2" value="7.3" spread="2.42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PTH.</title>
        <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PTH.</title>
            <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
            <units>pg/ml</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39.1" spread="2.60"/>
                  <measurement group_id="O2" value="52.6" spread="4.18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of 50,000 IU Vitamin D3 Supplementation on Serum Hydroxy Vitamin D Levels.</title>
        <description>Evaluation of the effectiveness of the dose regimen considered in this study as the product SmPC which will be measured through the assessment of serum 25 (OH)D along the trial period.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Effect of 50,000 IU Vitamin D3 Supplementation on Serum Hydroxy Vitamin D Levels.</title>
            <description>Evaluation of the effectiveness of the dose regimen considered in this study as the product SmPC which will be measured through the assessment of serum 25 (OH)D along the trial period.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48.2" spread="2.03"/>
                  <measurement group_id="O2" value="11.8" spread="0.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Reduction of body mass index to be &lt; 25-30 kg/m^2 after 3 months supplementaion of vitamin D3.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Body Mass Index</title>
            <description>Reduction of body mass index to be &lt; 25-30 kg/m^2 after 3 months supplementaion of vitamin D3.</description>
            <units>kg/m2</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25.6" spread="0.37"/>
                  <measurement group_id="O2" value="26.5" spread="0.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance and Improving Insulin Sensitivity After Vitamin D3 Supplementation for 3 Months.</title>
        <description>Reduction of insulin resistance and improving insulin sensitivity measured by HOMMA method through reducing fasting insulin to be &lt; 24 uU/ml after vitamin D3 supplementation for 3 months.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insulin Resistance and Improving Insulin Sensitivity After Vitamin D3 Supplementation for 3 Months.</title>
            <description>Reduction of insulin resistance and improving insulin sensitivity measured by HOMMA method through reducing fasting insulin to be &lt; 24 uU/ml after vitamin D3 supplementation for 3 months.</description>
            <units>uU/ml</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.9" spread="1.34"/>
                  <measurement group_id="O2" value="8.8" spread="1.69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Chromium Level After Supplementation With Vitamin D3.</title>
        <description>serum chromium level to be &gt; 0.05 and &lt; 0.5 ppm which will be assessed by measuring serum chromium level after supplementation of vitamin D3 for 3 months.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Chromium Level After Supplementation With Vitamin D3.</title>
            <description>serum chromium level to be &gt; 0.05 and &lt; 0.5 ppm which will be assessed by measuring serum chromium level after supplementation of vitamin D3 for 3 months.</description>
            <units>ppm</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.27" spread="0.01"/>
                  <measurement group_id="O2" value="0.27" spread="0.01"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement of Polycystic Ovary Syndrome Prognosis Through Decreasing Hirsutism Score &lt; 8 .</title>
        <description>improvement of Polycystic ovary syndrome prognosis which will be measured through decreasing hirsutism score &lt; 8 . A total of 9 body sites were assessed, the score ranging from 0 (no excessive terminal hair growth) to 36 (extensive terminal hair growth). A score of 8 or higher was considered as androgen excess (Ferriman and Gallwey, 1961).</description>
        <time_frame>3months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Improvement of Polycystic Ovary Syndrome Prognosis Through Decreasing Hirsutism Score &lt; 8 .</title>
            <description>improvement of Polycystic ovary syndrome prognosis which will be measured through decreasing hirsutism score &lt; 8 . A total of 9 body sites were assessed, the score ranging from 0 (no excessive terminal hair growth) to 36 (extensive terminal hair growth). A score of 8 or higher was considered as androgen excess (Ferriman and Gallwey, 1961).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.5" spread="0.93"/>
                  <measurement group_id="O2" value="16.7" spread="1.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PO4.</title>
        <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of PO4.</title>
            <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.3"/>
                  <measurement group_id="O2" value="1.2" spread="0.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of Ca.</title>
        <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 (Biodal 50.000IU)</title>
            <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluation of the Safety of the Dose Regimen of Vitamin D3 Supplementation Which Will be Measured by Assessing the Level of Ca.</title>
            <description>Evaluation of the safety of the dose regimen of vitamin D3 supplementation which will be measured by assessing the level of Ca, PO4 and PTH and/or reporting any adverse events through the trial period.</description>
            <units>mmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="0.02"/>
                  <measurement group_id="O2" value="2.3" spread="0.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Vitamin D supplementation for vitamin D deficient (&lt;20 ng/ml) women with 50,000 IU/week for 12 weeks did not lead to any side effects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3 (Biodal 50.000IU)</title>
          <description>50,000 IU vitamin D3 (Biodal 50.000IU) coated tablets by oral route
50.000IU Vitamin D3: 50.000IU Vitamin D3 (Biodal 50.000IU ) once weekly for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo coated tablet by oral route
placebo: placebo coated tablet by oral route</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was conducted only in the north of Jordan
Body composition was measured by bioelectrical impedance
Insulin resistance was assessed using the indirect method of assessment (HOMA)
The study was done exclusively on overweight women</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Hayder Al-Domi</name_or_title>
      <organization>Hayat Pharmaceutical industries</organization>
      <phone>00962 6 4162607 227</phone>
      <email>hpi@nol.com.jo</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
